|1.||Gow, James A: 7 articles (01/2014 - 09/2007)|
|2.||Waterbury, L David: 5 articles (12/2011 - 09/2008)|
|3.||Bucci, Frank A: 4 articles (12/2011 - 09/2008)|
|4.||McNamara, Timothy R: 4 articles (11/2011 - 08/2008)|
|5.||Fujishima, Hiroshi: 3 articles (01/2015 - 11/2004)|
|6.||Piotrowska-Gwóźdź, Anna: 2 articles (01/2015 - 01/2014)|
|7.||Wyględowska-Promieńska, Dorota: 2 articles (01/2015 - 01/2014)|
|8.||Piotrowska-Seweryn, Agnieszka: 2 articles (01/2015 - 01/2014)|
|9.||Mazur-Piotrowska, Grażyna: 2 articles (01/2015 - 01/2014)|
|10.||Maruyama, Yoko: 2 articles (08/2014 - 05/2009)|
09/01/2007 - "A greater proportion of bromfenac (64.0%) than placebo subjects (43.3%) achieved complete clearance of ocular inflammation at study day 15 (P<0.0001). "
01/01/2014 - "A significantly higher proportion of subjects treated with bromfenac 0.07% achieved complete clearance of ocular inflammation by day 15 and at day 15 compared with placebo (P < 0.0001). "
11/01/2011 - "The proportion of subjects who had cleared ocular inflammation by day 15 was significantly higher in the bromfenac 0.09% group than in the placebo group (P < 0.0001). "
09/01/2007 - "The effect of bromfenac on clearance of ocular inflammation was as early as study day 3 after initiation of treatment, compared with the placebo (8.4% vs. 1.2%, P = 0.0012). "
05/01/2015 - "Bromfenac was equally effective compared with PA in controlling inflammation. "
07/01/1998 - "The purpose of this study was to evaluate the analgesic efficacy and safety of five graded doses of bromfenac sodium in patients experiencing moderate to severe pain after the surgical removal of impacted third molar teeth. "
10/01/2010 - "Fifty-two percent of bromfenac-treated patients reported no pain by day 3, compared with 0% of untreated controls (P=0.023). "
09/01/2007 - "The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P<0.0001). "
09/01/1999 - "For three months preceding her illness, the patient was treated with bromfenac 25 mg po qid for arthritic pain. "
08/01/1999 - "Moreover, the findings suggest that 75 mg bromfenac might be suitable for fast but short relief of pain of non-inflammatory genesis."
01/01/2014 - "One of these medications, bromfenac ophthalmic solution, has a long and extensive history, with proven efficacy and safety in patients following cataract surgery. "
01/01/2014 - "The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery."
12/01/2010 - "Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes."
01/01/2014 - "Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials."
08/01/2015 - "Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery."
|4.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
01/01/2007 - "Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis."
06/01/2009 - "Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG."
06/01/2009 - "Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis."
01/01/2012 - "However, bromfenac also seems to be useful in other situations, such as refractive surgery, allergic conjunctivitis (not useful in dry eye), choroidal neovascularization, and even ocular oncology. "
11/01/2004 - "Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium."
|5.||Macular Degeneration (Age-Related Maculopathy)
11/01/2009 - "Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration."
11/01/2009 - "The purpose of this study was to assess the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration demonstrating persistent exudation despite monthly intravitreal antivascular endothelial growth factor therapy. "
01/01/2015 - "Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD."
01/01/2014 - "Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study."
10/01/2012 - "Topical bromfenac might reduce the frequency of ranibizumab over 6 months in eyes with relatively small age-related macular degeneration lesions."
|5.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|8.||Ophthalmic Solutions (Eye Drops)
|9.||Endothelial Growth Factors
|1.||Intraocular Lens Implantation
|4.||Oral Surgery (Maxillofacial Surgery)
|5.||Intraocular Lenses (Intraocular Lens)